RNA binding motif protein 12 (RBM12)

RNA binding motif protein 12 (RBM12) is a ubiquitously expressed, multi-domain RNA-binding protein that plays a regulatory role in post-transcriptional gene control, primarily by binding to untranslated regions of mRNA and influencing their stability and translation[1][2][3][4]. It contains several RNA recognition motifs, potential transmembrane domains, and proline-rich regions[1][2][3][4][5]. RBM12 acts in the nucleus and is involved in the negative regulation of fetal hemoglobin expression, making it relevant to hemoglobinopathies such as sickle cell disease and β‑thalassemia[1]. Truncating mutations in RBM12 have been linked to familial forms of psychosis and may influence susceptibility to schizophrenia[1][2][3]. In neuronal contexts, RBM12 represses G-protein-coupled receptor (GPCR)/cAMP/PKA signaling, and its deficiency can lead to hyperactivity of this pathway and associated transcriptional changes relevant to neuropsychiatric disorders[1]. Emerging evidence suggests RBM12 may also regulate cancer pathways via interactions with microRNAs[1]. No approved drugs are currently known to specifically target RBM12.

Other names

HRIHFB2091SWANKIAA0765SCZD19SH3/WW domain anchor protein in the nucleusRNA-binding protein 12